Bicara Therapeutics (BCAX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.82
- EPS estimate
- −$0.82
- EPS surprise
- −0.02%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 11, 2026
Bicara Therapeutics reported Q2 2026 results on August 11, 2026. It posted a loss of $0.82 per share, in line with the $0.82 estimate; the source records a 0.02% miss. No revenue was reported and no revenue estimate was given. A year earlier, in Q2 2025, the loss was $0.50 per share, so the loss widened by about 64%.
The record is short, with eight quarters from Q3 2024, and every one of them is a loss. Losses have grown since early 2025. The loss for the full 2025 fiscal year was $2.53 per share, and the first half of 2026 adds up to a $1.75 loss, against $1.18 in the first half of 2025. The widest quarterly loss in the table is Q3 2024, at $1.60 per share, and the narrowest is Q4 2024, at $0.39. Bicara has beaten the EPS estimate once in eight quarters, in Q2 2025, by 9.75%. The largest misses were Q3 2024 and Q1 2025.
Bicara reported Q3 on November 12, 2024 and November 10, 2025. That points to around mid-November 2026 for the Q3 2026 report. It will show whether the quarterly loss stays in the range of the last few quarters.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 11, 2026 | −$0.82 | −$0.82 | −0.02% | $0.00 | SEC |
| Q1 2026 | May 11, 2026 | −$0.65 | −$0.93 | −43.23% | $0.00 | SEC |
| Q4 2025 | Mar 30, 2026 | −$0.67 | −$0.68 | −1.16% | $0.00 | SEC |
| Q3 2025 | Nov 10, 2025 | −$0.54 | −$0.67 | −23.82% | $0.00 | SEC |
| Q2 2025 | Aug 12, 2025 | −$0.55 | −$0.50 | +9.75% | $0.00 | SEC |
| Q1 2025 | May 13, 2025 | −$0.42 | −$0.68 | −63.86% | $0.00 | SEC |
| Q4 2024 | Mar 27, 2025 | −$0.33 | −$0.39 | −18.47% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.41 | −$1.60 | −290.24% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Bicara Therapeutics (BCAX) last report earnings?
Bicara Therapeutics last reported on Aug 11, 2026, covering fiscal Q2 2026.
Did BCAX beat earnings estimates?
No. Bicara Therapeutics reported EPS of −$0.82 for Q2 2026 against a −$0.82 estimate — a 0.02% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.